Question-and-Answer Session
Operator
(Operator Instructions). Our first question is from the line of Gregory Brash - Sidoti & Company.
Gregory Brash - Sidoti & Company
Hi Jan, welcome aboard. Just want to start off and I know you’re not giving guidance out here for 2010, but you guys have talked about in the past 20% revenue growth and starting to see a lot of operating leverages as spending levels down on the NanoKnife, is that still the thought here or are we thinking more along the lines of some of the growth rates we’re seeing right now?
Jan Keltjens
Great question, sounds like you know me a little bit as well in the sense that we indeed do not give guidance yet for the following year. Let me make some holistic statements, and I kind of referred to that in my comments as well; I think we’ve got a lot of strength in various pockets of our business and I think if you take the entire portfolio, if you take our entire product line, certainly that is the goal we would have as such, but again at this point in time, we stay away from specific guidance and sometimes it may take a little while to get growth up to that kind of levels as well. This year, of course, we are heading at about 20% average, I think, year-to-date. That includes of course a favorable comparison because of the Diomed acquisition which we will lose in about a quarter, quarter and a half something like that, but the long-term aspiration certainly stays there.
Gregory Brash - Sidoti & Company
Okay, and then you touched on improving on some of the supply chain efficiency and narrowing down the R&D, just curious maybe when could we expect to see some of those changes taking place and where are we right now in the planned launch of the Centros Dialysis Catheter in addition to the Medron ports?
Jan Keltjens
The changes I’ve been talking about, it’s almost like a continual of change, and some of that started a few weeks ago already, pretty early on, is also facing into the reality that times have changed, developing products in the medical device field today takes a lot more effort than it used to, more regulations and all that, and I’m just of the strong belief that focus and picking the right programs in driving down with vigor is the right approach here. Specifically on Centros, we believe in the product and the teams are working on it and are picking the challenges that led to the recall a while ago. While doing that, they’re also improving some of the design details. We reviewed the program about 2 weeks ago; as I said, we’re very committed to that and there going to be a little while a wait before the product sees the market which is important to us, but it is probably more likely to see that in the second half of the fiscal year.
- To read the full transcript on Seeking Alpha, click here »
